Regulus Therapeutics Inc. (RGLS)

2.4700 -0.1800 (-6.79%) 市場開市。 截至 12:53PM EDT。

Regulus Therapeutics Inc.

4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
858 202 6300
https://www.regulusrx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 30

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Joseph P. Hagan M.B.A.	CEO & Director	958.23k	無	1969
Ms. Crispina Calsada CPA	Chief Financial Officer	579.3k	無	1970
Mr. Christopher Ray Aker J.D.	Senior VP, General Counsel & Corporate Secretary	575.94k	無	1961
Dr. Preston S. Klassen M.D., M.H.S.	President, Head of Research & Development and Director	無	無	1969
Mr. Daniel J. Penksa	VP of Finance & Controller	無	無	1986
Dr. Claire Susan Padgett M.S., M.T., Ph.D.	Senior Vice President of Clinical Operations	無	無	無
Dr. Rekha Garg M.D., M.S.	Senior Vice President of Clinical Development & Regulatory	無	無	無
Mr. Edmund Lee Ph.D.	Vice President of Translational Medicine	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

公司管治

截至 無 止，Regulus Therapeutics Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。